Literature DB >> 182681

Specific herpes simplex virus-induced incorporation of 5-iodo-5'-amino-2',5'-dideoxyuridine into deoxyribonucleic acid.

M S Chen, D C Ward, W H Prusoff.   

Abstract

5-Iodo-5'-amino-2',5'-dideoxyuridine (AIdUrd) is a novel thymidine analog which inhibits herpes simplex virus, type 1 (HS-1 virus) replication in the absence of detectable host toxicity. When murine, simian, or human cells in culture are treated with [125I]AIdUrd for up to 24 hours essentially none of the nucleoside becomes cell-associated. In contrast, upon HS-1 virus infection significant radiolabel is detected in both nucleotide pools and in DNA. The major acid-soluble metabolite has been shown by enzymic and chromatographic analysis to be the 5'-triphosphate of AIdUrd. DNA from HS-1 virus-infected Vero cells labeled with [14C]thymidine, 5-[125I]iodo-2'-deoxyuridine (IdUrd), or [125I]AIdUrd was isolated by buoyant density centrifugation and subjected to digestion by pancreatic DNase I, spleen DNase II, micrococcal nuclease, spleen, and venom phosphodiesterases. Analysis of the digestion products clearly indicate that AIdUrd is incorporated internally into the DNA structure. DNA containing AIdUrd therefore contains phosphoramidate (P-N) bonds, known to be extremely acid-labile. The selective HS-1 virus-induced phosphorylation of AIdUrd and its subsequent incorporation into DNA may account for the unique biological activity of the AIdUrd nucleoside.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 182681

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Detection of herpes simplex virus type 1 transcripts during latent infection in mice.

Authors:  J G Spivack; N W Fraser
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

2.  Effects of nucleoside analogs on Epstein-Barr virus-induced transformation of human umbilical cord leukocytes and Epstein-Barr virus expression in transformed cells.

Authors:  E E Henderson; W K Long; R Ribecky
Journal:  Antimicrob Agents Chemother       Date:  1979-01       Impact factor: 5.191

Review 3.  Specific targets for antiviral drugs.

Authors:  E De Clercq
Journal:  Biochem J       Date:  1982-07-01       Impact factor: 3.857

4.  Focus formation and neoplastic transformation by herpes simplex virus type 2 inactivated intracellularly by 5-bromo-2'-deoxyuridine and near UV light.

Authors:  M M Manak; L Aurelian; P O Ts'o
Journal:  J Virol       Date:  1981-10       Impact factor: 5.103

5.  (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent.

Authors:  E De Clercq; J Descamps; P De Somer; P J Barr; A S Jones; R T Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

6.  Inhibition of glycosylation of bovine herpesvirus 1 glycoproteins by the thymidine analog (E)-5-(2 Bromovinyl)-2'-deoxyuridine.

Authors:  V Misra; R C Nelson; L A Babiuk
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

7.  5'-Amino-5'-deoxythymidine: synthesis, specific phosphorylation by herpesvirus thymidine kinase, and stability to pH of the enzymically formed diphosphate derivative.

Authors:  M S Chen; G T Shiau; W H Prusoff
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

8.  Expression of herpes simplex virus type 1 latency-associated transcripts in the trigeminal ganglia of mice during acute infection and reactivation of latent infection.

Authors:  J G Spivack; N W Fraser
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

9.  On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine.

Authors:  H S Allaudeen; J W Kozarich; J R Bertino; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

10.  Tetrahydrouridine specifically facilitates deoxycytidine incorporation into herpes simplex virus DNA.

Authors:  T W North; C K Mathews
Journal:  J Virol       Date:  1981-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.